Form 4: Elanco Director Kirk McDonald Receives Annual Equity Award

Elanco Animal Health Inc. director Kirk P. McDonald was granted 10,314 deferred stock units as part of an annual equity award for non-employee board members.

Summary

• Kirk P. McDonald, a Director of Elanco Animal Health Inc., received an annual equity award.
• The award consists of 10,314 deferred stock units of common stock.
• The transaction date for this acquisition was 11/28/2025.
• The acquisition price per share was $0, indicating a grant rather than a purchase.
• Following this transaction, Mr. McDonald beneficially owns 88,714 shares of common stock directly.
• This grant is part of the annual equity awards provided to non-employee members of the Issuer's Board of Directors.

Sentiment

Score: 7

Explanation: The filing reports a routine, expected annual equity award to a director, which is a positive for the individual recipient and indicates standard corporate governance practices. It does not contain any negative information about the company's operations or financial health.

Positives

• The grant of 10,314 deferred stock units to Director Kirk P. McDonald aligns his interests with shareholders.
• This is a routine annual equity award, indicating stable compensation practices for non-employee directors.

Negatives

• No specific negative points are identified in this routine insider transaction filing.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, beyond the future transaction date for the stock grant.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

This filing details a routine compensation event for a non-employee director, which is a standard practice across publicly traded companies in various industries, including animal health. It does not provide insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• The grant of deferred stock units as an annual equity award to non-employee directors is a common compensation practice across industries, including the pharmaceutical and animal health sectors. This aligns with typical corporate governance structures for director remuneration, often seen in companies comparable to Elanco Animal Health Inc.

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The grant of deferred stock units to Kirk P. McDonald, a director, constitutes a related party transaction, which is a standard form of compensation for non-employee board members.

Stakeholder Impact

• Shareholders: The grant represents a form of non-cash compensation to a director, aligning his interests with long-term shareholder value. It is a routine expense for the company.
• Employees: No direct impact on employees is indicated.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this Form 4 filing, beyond the future transaction date of the grant.

Key Dates

Keywords

Elanco Animal Health, ELAN, Kirk P. McDonald, Form 4, Insider Transaction, Equity Award, Deferred Stock Units, Director Compensation, Stock Grant